MX2016014780A - Metodos y composiciones de dasotralina para el tratamiento del adhd. - Google Patents

Metodos y composiciones de dasotralina para el tratamiento del adhd.

Info

Publication number
MX2016014780A
MX2016014780A MX2016014780A MX2016014780A MX2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A
Authority
MX
Mexico
Prior art keywords
dasotraline
adhd
treatment
compositions
methods
Prior art date
Application number
MX2016014780A
Other languages
English (en)
Inventor
D Loebel Antony
S Koblan Kenneth
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2016014780A publication Critical patent/MX2016014780A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

Se describen formas de dosificación y regímenes de tratamiento que emplean dasotralina para tratar el Trastorno por Déficit de Atención con Hiperactividad (ADHD). Las composiciones descritas en el presente documento no exhiben potencial de abuso.
MX2016014780A 2014-05-13 2015-05-12 Metodos y composiciones de dasotralina para el tratamiento del adhd. MX2016014780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992588P 2014-05-13 2014-05-13
PCT/US2015/030342 WO2015175514A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Publications (1)

Publication Number Publication Date
MX2016014780A true MX2016014780A (es) 2017-07-25

Family

ID=54480544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014780A MX2016014780A (es) 2014-05-13 2015-05-12 Metodos y composiciones de dasotralina para el tratamiento del adhd.

Country Status (10)

Country Link
US (1) US20170266133A1 (es)
EP (1) EP3142999A4 (es)
JP (1) JP2017515858A (es)
KR (1) KR20170003677A (es)
CN (1) CN106660936A (es)
AU (1) AU2015259337A1 (es)
CA (1) CA2948829A1 (es)
IL (1) IL248846A0 (es)
MX (1) MX2016014780A (es)
WO (1) WO2015175514A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512057A (ja) * 2018-01-19 2021-05-13 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 経口製剤
US20210386689A1 (en) * 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CA2498152C (en) * 2002-09-16 2012-01-10 Sepracor Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
BR112012013325B8 (pt) * 2009-12-04 2021-05-25 Sunovion Pharmaceuticals Inc composição farmacêutica e uso
EP2707000A4 (en) * 2011-05-13 2014-11-26 Dainippon Sumitomo Pharma Co TREATMENT AND CONTROL OF CNS DISORDERS

Also Published As

Publication number Publication date
IL248846A0 (en) 2017-01-31
EP3142999A4 (en) 2017-12-27
KR20170003677A (ko) 2017-01-09
CA2948829A1 (en) 2015-11-19
JP2017515858A (ja) 2017-06-15
US20170266133A1 (en) 2017-09-21
WO2015175514A1 (en) 2015-11-19
EP3142999A1 (en) 2017-03-22
AU2015259337A1 (en) 2016-12-08
CN106660936A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
NZ731467A (en) Anti-tim3 antibodies and methods of use
IL253979B (en) Methods, preparations and kits for cancer treatment
GB2541571A (en) Pharmaceutical compositions
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
HK1244429A1 (zh) 特別用於治療注意力缺陷障礙的方法和組合物
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
MX2017012553A (es) Compuestos espirociclicos.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12017501864A1 (en) Compositions and methods for treating autism
PH12016501838A1 (en) Compounds and their methods of use
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2016014780A (es) Metodos y composiciones de dasotralina para el tratamiento del adhd.
MX2016014768A (es) Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd.
IL278763A (en) Methods for treating attention deficit hyperactivity disorder